The Use of 1.5-Anhydroglucitol for Monitoring Glycemic Control in Islet Transplant Recipients
We evaluated whether 1,5-anhydroglucitol (1,5-AG) (GlycoMark ® ), a test for measuring postprandial glucose and glucose variability, could be a tool for assessing short-term glycemic control in islet cell transplant (ICT) subjects. Data of 21 subjects, with type 1 DM and allogenic islet transplantat...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2014-10-01
|
| Series: | Cell Transplantation |
| Online Access: | https://doi.org/10.3727/096368913X669734 |
| _version_ | 1818940518077300736 |
|---|---|
| author | Eduardo Moraes Leao Peixoto Nujen Colak Bozkurt Shari Messinger Maria Isabel Del Olmo García Vincenzo Lauriola Andrea Corrales Eva Herrada Camillo Ricordi Rodolfo Alejandro M.D. |
| author_facet | Eduardo Moraes Leao Peixoto Nujen Colak Bozkurt Shari Messinger Maria Isabel Del Olmo García Vincenzo Lauriola Andrea Corrales Eva Herrada Camillo Ricordi Rodolfo Alejandro M.D. |
| author_sort | Eduardo Moraes Leao Peixoto |
| collection | DOAJ |
| description | We evaluated whether 1,5-anhydroglucitol (1,5-AG) (GlycoMark ® ), a test for measuring postprandial glucose and glucose variability, could be a tool for assessing short-term glycemic control in islet cell transplant (ICT) subjects. Data of 21 subjects, with type 1 DM and allogenic islet transplantation, who had concomitant fructosamine, HbA1c, 1,5-AG ( n = 85 samples), and capillary glucose self-monitoring measurements ( n = 2,979) were analyzed retrospectively at different time points after ICT. A significant negative association was observed between 1,5-AG and HbA1c ( p = 0.02), but not with fructosamine. When HbA1c was divided in quartiles as <5.6, 5.6–5.9, 5.9–6.2, and >6.2, a decrease of an estimated 0.70 ± 0.30 μg/ml in 1,5-AG was associated with each quartile of increase in HbA1c ( p < 0.0001). There was a significant decline of 1.64 ± 0.3mg/dl in postprandial glucose values for each 1 unit increase in 1,5-AG ( p < 0.0001). For those with HbA1c ≥ 6.0% when 1,5-AG was ≥8.15 μg/ml, the mean estimated glucose level was 103.71 ± 3.66 mg/dl, whereas it was 132.12 ± 3.71 mg/ dl when 1,5-AG was <8.15 μg/ml. The glucose variability (Glu max - Glu min ) in subjects with 1,5-AG <8.15 μg/ml was 46.23 mg/dl greater than the subjects with 1,5-AG ≥8.15 μg/ml (HbA1c ≥ 6.0%). There was no significant association between GlycoMark and glucose variability where HbA1c < 6%. 1,5-AG significantly associated with postprandial glucose levels and glucose variability in ICT recipients with near-normal HbA1c (6.0–6.5%) levels. These findings suggest that 1,5-AG can be used to differentiate those ICT subjects with higher glucose variability despite having near-normal HbA1c. However, prospective studies are needed to evaluate the association between GlycoMark levels and the parameters of graft dysfunction/failure. |
| first_indexed | 2024-12-20T06:40:55Z |
| format | Article |
| id | doaj.art-928c15624b4e49ccaf0b3b51c5dc9036 |
| institution | Directory Open Access Journal |
| issn | 0963-6897 1555-3892 |
| language | English |
| last_indexed | 2024-12-20T06:40:55Z |
| publishDate | 2014-10-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Cell Transplantation |
| spelling | doaj.art-928c15624b4e49ccaf0b3b51c5dc90362022-12-21T19:49:52ZengSAGE PublishingCell Transplantation0963-68971555-38922014-10-012310.3727/096368913X669734The Use of 1.5-Anhydroglucitol for Monitoring Glycemic Control in Islet Transplant RecipientsEduardo Moraes Leao Peixoto0Nujen Colak Bozkurt1Shari Messinger2Maria Isabel Del Olmo García3Vincenzo Lauriola4Andrea Corrales5Eva Herrada6Camillo Ricordi7Rodolfo Alejandro M.D.8Diabetes Research Institute, Miami, FL, USADiabetes Research Institute, Miami, FL, USADivision of Biostatistics, Department of Epidemiology and Public Health, University of Miami Miller School of Medicine, Miami, FL, USADepartment of Endocrinology and Nutrition, University Hospital La Fe, Valencia, SpainFacoltá di Scienze Motorie, Universitá degli Studi di Milano, Milano, ItalyDiabetes Research Institute, Miami, FL, USADiabetes Research Institute, Miami, FL, USAJackson Memorial Hospital-University of Miami Transplant Institute, University of Miami Miller School of Medicine, Miami, FL, USA†Department of Medicine, University of Miami Miller School of Medicine, Miami, FL, USAWe evaluated whether 1,5-anhydroglucitol (1,5-AG) (GlycoMark ® ), a test for measuring postprandial glucose and glucose variability, could be a tool for assessing short-term glycemic control in islet cell transplant (ICT) subjects. Data of 21 subjects, with type 1 DM and allogenic islet transplantation, who had concomitant fructosamine, HbA1c, 1,5-AG ( n = 85 samples), and capillary glucose self-monitoring measurements ( n = 2,979) were analyzed retrospectively at different time points after ICT. A significant negative association was observed between 1,5-AG and HbA1c ( p = 0.02), but not with fructosamine. When HbA1c was divided in quartiles as <5.6, 5.6–5.9, 5.9–6.2, and >6.2, a decrease of an estimated 0.70 ± 0.30 μg/ml in 1,5-AG was associated with each quartile of increase in HbA1c ( p < 0.0001). There was a significant decline of 1.64 ± 0.3mg/dl in postprandial glucose values for each 1 unit increase in 1,5-AG ( p < 0.0001). For those with HbA1c ≥ 6.0% when 1,5-AG was ≥8.15 μg/ml, the mean estimated glucose level was 103.71 ± 3.66 mg/dl, whereas it was 132.12 ± 3.71 mg/ dl when 1,5-AG was <8.15 μg/ml. The glucose variability (Glu max - Glu min ) in subjects with 1,5-AG <8.15 μg/ml was 46.23 mg/dl greater than the subjects with 1,5-AG ≥8.15 μg/ml (HbA1c ≥ 6.0%). There was no significant association between GlycoMark and glucose variability where HbA1c < 6%. 1,5-AG significantly associated with postprandial glucose levels and glucose variability in ICT recipients with near-normal HbA1c (6.0–6.5%) levels. These findings suggest that 1,5-AG can be used to differentiate those ICT subjects with higher glucose variability despite having near-normal HbA1c. However, prospective studies are needed to evaluate the association between GlycoMark levels and the parameters of graft dysfunction/failure.https://doi.org/10.3727/096368913X669734 |
| spellingShingle | Eduardo Moraes Leao Peixoto Nujen Colak Bozkurt Shari Messinger Maria Isabel Del Olmo García Vincenzo Lauriola Andrea Corrales Eva Herrada Camillo Ricordi Rodolfo Alejandro M.D. The Use of 1.5-Anhydroglucitol for Monitoring Glycemic Control in Islet Transplant Recipients Cell Transplantation |
| title | The Use of 1.5-Anhydroglucitol for Monitoring Glycemic Control in Islet Transplant Recipients |
| title_full | The Use of 1.5-Anhydroglucitol for Monitoring Glycemic Control in Islet Transplant Recipients |
| title_fullStr | The Use of 1.5-Anhydroglucitol for Monitoring Glycemic Control in Islet Transplant Recipients |
| title_full_unstemmed | The Use of 1.5-Anhydroglucitol for Monitoring Glycemic Control in Islet Transplant Recipients |
| title_short | The Use of 1.5-Anhydroglucitol for Monitoring Glycemic Control in Islet Transplant Recipients |
| title_sort | use of 1 5 anhydroglucitol for monitoring glycemic control in islet transplant recipients |
| url | https://doi.org/10.3727/096368913X669734 |
| work_keys_str_mv | AT eduardomoraesleaopeixoto theuseof15anhydroglucitolformonitoringglycemiccontrolinislettransplantrecipients AT nujencolakbozkurt theuseof15anhydroglucitolformonitoringglycemiccontrolinislettransplantrecipients AT sharimessinger theuseof15anhydroglucitolformonitoringglycemiccontrolinislettransplantrecipients AT mariaisabeldelolmogarcia theuseof15anhydroglucitolformonitoringglycemiccontrolinislettransplantrecipients AT vincenzolauriola theuseof15anhydroglucitolformonitoringglycemiccontrolinislettransplantrecipients AT andreacorrales theuseof15anhydroglucitolformonitoringglycemiccontrolinislettransplantrecipients AT evaherrada theuseof15anhydroglucitolformonitoringglycemiccontrolinislettransplantrecipients AT camilloricordi theuseof15anhydroglucitolformonitoringglycemiccontrolinislettransplantrecipients AT rodolfoalejandromd theuseof15anhydroglucitolformonitoringglycemiccontrolinislettransplantrecipients AT eduardomoraesleaopeixoto useof15anhydroglucitolformonitoringglycemiccontrolinislettransplantrecipients AT nujencolakbozkurt useof15anhydroglucitolformonitoringglycemiccontrolinislettransplantrecipients AT sharimessinger useof15anhydroglucitolformonitoringglycemiccontrolinislettransplantrecipients AT mariaisabeldelolmogarcia useof15anhydroglucitolformonitoringglycemiccontrolinislettransplantrecipients AT vincenzolauriola useof15anhydroglucitolformonitoringglycemiccontrolinislettransplantrecipients AT andreacorrales useof15anhydroglucitolformonitoringglycemiccontrolinislettransplantrecipients AT evaherrada useof15anhydroglucitolformonitoringglycemiccontrolinislettransplantrecipients AT camilloricordi useof15anhydroglucitolformonitoringglycemiccontrolinislettransplantrecipients AT rodolfoalejandromd useof15anhydroglucitolformonitoringglycemiccontrolinislettransplantrecipients |